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Abstract
Background: Jamestown Canyon virus (JCV), family Bunyaviridae, is a mosquito-borne pathogen endemic in the
United States and Canada that can cause encephalitis in humans and is considered an emerging threat to public
health. The virus is genetically similar to Inkoo virus circulating in Europe, suggesting that much of the northern
hemisphere contains JCV or similar variants.
Results: We have completed the sequence of three isolates of JCV collected in geographically diverse locations
over a 57 year time span. The nucleotide identity for the three strains is 90, 83, and 85% for the S, M, and L
segments respectively whereas the percent identify for the predicted amino acid sequences of the N, NSS, M poly,
GN,N S M,G C, and L proteins was 97, 91, 94, 98, 91, 94, and 97%, respectively. In Swiss Webster mice, each JCV
isolate exhibits low neuroinvasiveness but high infectivity. Two of the three JCV isolates were highly neurovirulent
after IC inoculation whereas one isolate, JCV/03/CT, exhibited low neurovirulence. In rhesus monkeys, JCV infection
is accompanied by a low-titered viremia, lack of clinical disease, but a robust neutralizing antibody response.
Conclusions: The first complete sequence of JCV is reported for three separate isolates, and a relatively high level
of amino acid sequence conservation was observed even for viruses isolated 57 years apart indicating that the
virus is in relative evolutionary stasis. JCV is highly infectious for mice and monkeys, and these animals, especially
mice, represent useful experimental hosts for further study.
Background
Jamestown Canyon virus (JCV), family Bunyaviridae,i sa
mosquito-borne pathogen endemic in the United States
and Canada and considered an emerging threat to pub-
lic health [1]. JCV is a member of the California ser-
ogroup of viruses in the genus Orthobunyavirus and
contains three genome segments, small (S), medium
(M), and large (L) consisting of a single strand of nega-
tive-sense RNA. JCV was first isolated from Culiseta
inornata mosquitoes collected near Jamestown Canyon,
northwest of Boulder, CO [2]. The serogroup contains
members found on five continents that include human
pathogens such as La Crosse (LACV) and snowshoe
hare viruses in North America; Guaroa virus in North
and South America; Inkoo and Tahyna viruses in
Europe; and Lumbo virus in Africa.
JCV is distributed over a large geographic range,
including much of the United States and Canada. This
broad range overlaps with other orthobunyaviruses, such
as La Crosse, Trivittatus, and snowshoe hare, and raising
the possibility for generation of viruses with reassorted
genome segments [1,3,4]. The principal vectors for JCV
are Aedes and Ochlerotatus species, with virus isolations
made from 26 species of mosquitoes and 3 species of
tabanid flie [3,5]. In the US, white-tailed deer are the
primary amplifying host, but mule deer, sika deer,
moose, caribou, elk and bison can be naturally infected
[1,6-9]. Livestock are also susceptible to infection with
virus being isolated from lesions on a horse and antibo-
dies detected in both horses and goats [8,10]. It has
been suggested that white-tailed deer populations living
close to human residents have been responsible for the
observed rise in JCV seroprevalence in humans [9]. Ser-
oprevalance among white-tailed deer in North Carolina,
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Although JCV does not appear to cause disease in adult
deer, it has been shown to be teratogenic, with JCV
infection during pregnancy resulting in fawns born
paralyzed, dead or aborted [12]. Serum cross neutraliza-
tion studies have suggested JCV, South River virus, and
Jerry Slough virus, all endemic to the United States, are
antigenically related [3,13,14]. The virus is genetically
similar to Inkoo virus circulating in Europe, suggesting
much of the northern hemisphere contains JCV or simi-
lar variants [15,16].
In humans, JCV infection causes a mild febrile illness
that can lead to infection of the central nervous system
(CNS) resulting in meningitis and encephalitis. Unlike
LACV, which mainly causes serious disease in children,
JCV appears to cause disease predominantly in adults
[17]. JCV disease is generally associated with headache,
fever, neck stiffness, photophobia, nausea, vomiting, and
seizures [18,19]. Respiratory involvement has been
reported for JCV [12]. Although JCV infection has been
confirmed by PCR of a brain biopsy, human isolates of
JCV have not been reported [18]. Serological studies of
residents of Alaska indicate an overall JCV infection rate
of 17.6% [1]. By age 15, 17% of the Alaskan population
has been exposed to JCV, and after age 15, seropreva-
lence increases to 24 - 30% with 25% of the population
showing serological evidence of infection with multiple
orthobunyaviruses [1]. JCV seropositivity rates in the
continental United States range from 3.5-12.9% in New
York, 2.5-10% in Wisconsin, 3.0-15% in Indiana, and
27.7% in Michigan [12]. The precise incidence of CNS
disease attributable to JCV is unknown, although retro-
spective analysis of serum collected from patients with
CNS disease in New York State between 1966 and 1981
indicated that 41 cases resulted from JCV infection [17].
Orthobunyavirus infection of animals, and most likely
humans, during pregnancy has the potential for terato-
genicity [20]. It is evident that the majority of JCV infec-
tions are subclinical or associated with mild symptoms.
Little is understood about the genetic relationship of
JCV isolates from different regions of the United States.
We sought to generate complete genome sequences
including the previously unreported L segment
sequence, with encodes the RNA dependent RNA poly-
merase (RDRP). Here we describe the complete genome
sequence of three JCV isolates and their level of neuro-
virulence and neuroinvasiveness in Swiss Webster mice.
We also describe the first reported infection of non-
human primates with JCV that resulted in viremia of
short duration in the absence of clinical disease. Since
one of the long-term goals of our laboratory is the
development of a live-attenuated virus vaccine for one
or more members of the California serogroup viruses,
the characterization of JCV was seen as an important
step in this process. The mouse model we developed
will be useful for studying the pathogenesis of the infec-
tion in the central nervous system, and the mouse and
monkey models will be useful for future testing of atte-
nuated vaccine candidates.
Results
Sequence analysis of viral genomes
The complete sequence of three JCV strains isolated
from mosquitoes in Colorado or Connecticut over a
span of 57 years was determined (Table 1, with acces-
sion numbers). This sequence analysis permitted an
assessment of the genetic diversity of JCV isolated in
different regions of the United States over this period of
time. Both original isolates and biologically cloned deri-
vatives were analyzed when possible to permit a com-
parison of a defined genomic sequence with a virulence
phenotype in mice.
The genome sequence of JCV/61/CO-cl differed from
its uncloned parental virus at two loci in the M seg-
ment: G1091A, which resulted in a codon change of
aspartic acid to asparagine at codon 347, and T2731C, a
synonymous change for codon 893. The genome
sequence of JCV/03/CT-cl sequence differed from its
uncloned parental virus at one locus on the M segment:
G629A, which resulted in a codon change of glycine to
serine at codon 193. The uncloned parental stock of
JCV/04/CT-cl contained a mixture of JCV and West
Nile virus, so genetic comparisons or mouse inocula-
tions were not completed with the uncloned stock.
However, due to the limited number of available JCV
isolates, the cloned stock of JCV/04/CT was not
excluded from further analysis.
The length of the respective open reading frames
(ORF) of the S, M, and L segments was identical for
each JCV isolate, as was the length of the 3’ untranslated
regions (UTR) (Table 2). However, the length of the 5’
UTR differed among the isolates (Table 2). The JCV
strains share a minimum nucleotide identity for the S,
M, and L segments of 90, 83, and 85%, respectively
(Table 3). The predicted respective protein sequence
lengths for the N, NSS,Mp o l y p r o t e i n ,G N,N S M,G C,
and L proteins were identical for the three JCV strains
(Table 4). The minimum percent identity for the pre-
dicted amino acid sequences of the N, NSS, M polypro-
tein, GN,N S M,G C, and L proteins were 97, 91, 94, 98,
91, 94, and 97%, respectively. The GN protein was the
most conserved with less than 2% divergence (Table 4).
Complete predicted protein alignments are presented in
Figure 1, 2, and 3.
Sequence of the non-coding regions of JCV were more
diverse than that observed for the related LACV [21].
The M segment 3’ U T Rw a st h em o s th i g h l yc o n s e r v e d
with only 2 differences from the consensus (Figure 4A).
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nucleotide sequence (Table 2, Figure 4B). Within both
the 3’ and 5’ UTR, nucleotide divergence was greatest in
the region adjacent to the ORF with the nucleotides in
the terminal 50% of the UTRs being highly conserved.
In vitro replication kinetics
The kinetics of in vitro replication of JCV/61/CO-cl,
JCV/03/CT-cl, and JCV/04/CT-cl was compared in Vero
and C6/36 cells (Figure 5). Growth kinetics in Vero cells
suggest a complete replication cycle is obtained in less
than 8 hours with all three isolates reaching peak titers
of approximately 10
7 PFU/mL within 24 hours. All three
isolates replicated more slowly in C6/36 cells with peak
titers reached within 72 hours. Cytopathic effects (CPE)
associated with JCV infection of Vero cells consisted of
cell rounding and detachment from the flask beginning
at 24 hours post-infection and complete destruction of
the monolayer by 72 hours. CPE was not observed in
C6/36 cells infected with JCV.
JCV pathogenesis in mice
A low level of neuroinvasiveness, LD50 greater than 4.0
log10 PFU, was observed following intraperitoneal inocu-
lation of weanling mice with any of the five JCV pre-
parations (Table 5). However, the viruses differed in
their neurovirulence after IC inoculation, with JCV/61/
CO-cl and its uncloned parent virus and JCV/04/CT-cl
both being highly neurovirulent, whereas JCV/03/CT-cl
and its uncloned parent virus were only minimally neu-
rovirulent. All JCV isolates tested were highly infectious
f o rS w i s sW e b s t e rm i c eb yb o t hI Pa n dI Cr o u t e si n d i -
cating that the lack of neuroinvasiveness or neuroviru-
lence for any given virus was not due to reduced
infectivity (Table 5). Clinical disease in mice infected
with either JCV/61/CO-cl (or parent) and JCV/04/CT-cl
included lethargy, tremors, seizures, circling, and limb
paralysis.
Inoculation of rhesus monkeys with JCV/61/CO-cl
To develop a non-human primate model of JCV infec-
tion model for testing of future vaccine candidates, rhe-
sus monkeys were inoculated with 10
5 PFU of
biologically-cloned JCV/61/CO-cl, which was shown to
be highly virulent in mice. Illness was not observed in
any monkey following subcutaneous inoculation of
virus. Viremia was detected in 75% of monkeys with
titers ranging from 0.7 - 3.0 log10 PFU/mL on day 2 and
1.9 - 2.0 log10 PFU/mL on day 4 (Table 6). Virus was
not detected in any serum samples collected after day 4.
All monkeys developed neutralizing antibody responses
against JCV/61/CO-cl with a geometric mean titer of
171 on day 28 post-inoculation. Rhesus immune serum
against JCV/61/CO-cl also neutralized JCV/03/CT-cl
Table 1 Passage history and geographic location of isolates of Jamestown Canyon viruses
Virus Strain Site of isolation Vector Passage history
a Accession number
JCV/61/CO 61V2235
c Colorado Culiseta inornata MB, Vero 2 n/a
d
JCV/61/CO-cl
b MB, Vero 6 HM007350-2
JCV/03/CT 3573-03 Connecticut Ochlerotatus abserratus Vero 2 n/a
JCV/03/CT-cl
b Vero 6 HM007353-5
JCV/04/CT-cl
b 3324-04M Connecticut Ochlerotatus canadensis Vero 5 HM007356-8
aCell/tissue type followed by number of passages. MB = mouse brain, total number of passages unknown.
bBiologically-cloned derivative.
cPrototype strain.
dSequence not submitted.
Table 2 Segment lengths and UTR/coding region lengths
among JCV strains
Length (nucleotides) for indicated
virus
Segment Region JCV/61/CO-
cl
JCV/03/CT-
cl
JCV/04/CT-
cl
S3 ’ UTR 72 72 72
N ORF 705 705 705
NSs ORF 276 276 276
5’ UTR 214 209 212
Segment
total:
991 986 989
M3 ’ UTR 52 52 52
Polyprotein ORF 4332 4332 4332
5’ UTR 126 126 125
Segment
total:
4510 4510 4509
L3 ’ UTR 57 57 57
L ORF 6789 6789 6789
5’ UTR 114 111 114
Segment
total:
6960 6957 6960
Table 3 Percent nucleotide identity of the JCV S, M, and
L segments amongst the three viruses
Percent nucleotide identity by
segment
Virus pair S M L
JCV/61/CO-cl & JCV/03/CT-cl 91 83 85
JCV/61/CO-cl & JCV/04/CT-cl 90 84 91
JCV/03/CT-cl & JCV/04/CT-cl 92 85 85
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of all three viruses (Table 6). The GMT neutralizing
antibody titer was highest to JCV/04/CT-cl despite pri-
mary infection with JCV/61/CO-cl suggesting slight dif-
ferences in sensitivity of the three strains to
neutralization.
Conclusions
The first complete sequence of three JCV isolates col-
lected over a 57 year time span from two geographically
distant regions is reported. The length of the coding
regions for each of the predicted proteins was identical
for each of the three viruses as were the length of each 3’
UTR. The length of each 5’ UTR showed only minor var-
iations. JCV is moderately diverse at the nucleotide level
but less so at the amino acid level. There is greater
sequence divergence in the areas of 3’ and 5’ UTR that
are adjacent to the ORF and, conversely, greater conser-
vation exists near the termini. The genetic reasons for
this difference in sequence conservation were not
defined. This genetic diversity in these terminal regions is
much more so than described for LACV [21]. The amino
acid sequences in the ORFs show only modest sequence
divergence with percent identity for the predicted pro-
teins ranging from 91 to 98%. This is relatively modest
for viruses isolated 57 years apart in two geographically
distinct regions. The modest JCV sequence diversity seen
in this study may represent viruses that circulate in sepa-
rate ecological niches. This theory is supported by Arm-
strong et al. who used sub-regions of the S, M and L
segments to identified two major lineages of JCV in Con-
n e c t i c u ta n dd e m o n s t r a t e dt h a tt h e i rg e n e t i cd i v e r s i t y
correlated with their geographic location of isolation
[22]. One isolate from of each of these lineages was
included in this study.
JCV was evaluated for pathogenesis in mice to deter-
mine if CNS disease develops with each of the three
strains and one virus strain was evaluated in monkeys,
which were used as surrogates of the human host. The
three strains were highly infectious for mice but were
only weakly neuroinvasive following intraperitoneal
inoculation. However, the three strains differed in their
neurovirulence following inoculation directly into the
brain. JCV/04/CT and JCV/61/CO were highly neuro-
virulent (LD50 <1 . 4l o g 10 PFU) whereas JCV/03/CT-cl
and its uncloned parent virus were only weakly neuro-
virulent (LD50 >3 . 6l o g 10 PFU). This phenotype was
somewhat surprising since all three JCV isolates repli-
cated equally well in mammalian Vero cells. Since
neither JCV/03/CT-cl nor JCV/04/CT-cl were previously
Table 4 Percent amino acid identity of the JCV predicted proteins amongst the three viruses
Percent amino acid identity (total protein length in amino acids)
Virus pair N (235) NSs (92) M poly (1444) GN
a (286) NSM
b (163) GC
c (969) L (2263)
JCV/61/CO-cl & JCV/03/CT-cl 97 93 94 98 91 94 97
JCV/61/CO-cl & JCV/04/CT-cl 98 92 94 99 98 94 99
JCV/03/CT-cl & JCV/04/CT-cl 97 91 96 99 91 96 97
a For this comparison, GN is defined as amino acids 16-301 of the M polyprotein.
b For this comparison, NSM is defined as amino acids 302-464 of the M polyprotein.
c For this comparison, GC is defined as amino acids 476-1444 of the M polyprotein.
SSegment
 
N protein 
 
JCV/CO/61cl  .............................................................................S...................... 100 
JCV/CT/03cl  ................................V..A................................................................ 
JCV/CT/04cl  .................................VS................................................................. 
Consensus    MGDLVFYDVASTGANGFDPDAGFVAFMADHGESINLSAVRIFFLNAAKAKAALARKPERKATPKFGEWQVEIVNNHFPGNRNNPIGNNDLTIHRLSGYLA 
 
JCV/CO/61cl  .......NS........................................................................................... 200 
JCV/CT/03cl  ........E.............................................V............................................. 
JCV/CT/04cl  ........T........................................................................................... 
Consensus    RWVLEHFTXDDDESQRELIRSTIINPIAESNGIHWNNGPEIYLSFFPGTEMFLEIFKFYPLTIGIYRVKHGMMDPQYLKKALRQRYGTLTAEKWMAQKTV 
 
 
JCV/CO/61cl  ................................... 235 
JCV/CT/03cl  ................................... 
JCV/CT/04cl  ................................... 
Consensus    LIAKSLKDVEQLKWGRGGLSDAARTFLIKFGVKLP 


NSs protein 
 
JCV/CO/61cl  ........................ES.......................................S.......................... 92 
JCV/CT/03cl  .........................K...W..........................................G................P.. 
JCV/CT/04cl  .......................M.N..V............................N......K........................... 
Consensus    MMSHPQVQMDLIQMQGLWHLWLTTGXLSICQPLGSSSLMQQKPKLLSLVNRSGKLLLSLESGRWRLSIIIFLETGTTQLVTTILPSIGFQDI 
Figure 1 Amino acid alignment of the predicted coding regions of the S segment. The consensus sequence consists of two or more
sequences sharing the same amino acid residue at a given position and areas of no clear consensus are indicated with an “X”.
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not appear that passage history was a factor in this phe-
notype. The genetic basis underlying the difference in
neurovirulence between the JCV strains was not further
studied.
To evaluate JCV infection in a non-human primate
model, we infected JCV seronegative rhesus monkeys with
the prototype strain JCV/61/CO-cl. All monkeys were
infected, and viremia developed that was detected on days
2 and 4 post-infection and that reached a maximum titer
of 3.0 log10 PFU/mL. Viremia has not been described in
human JCV infections, probably because virus replicates
only transiently in the periphery and is cleared before
signs of encephalitis become apparent. Infection of rhesus
monkeys did not result in any clinical disease, including
symptoms of CNS infection, but a robust serum neutraliz-
ing antibody response developed in the monkeys. This
experience with JCV was similar to that observed with
Msegment
 
M polyprotein 
                             GN  
JCV/CO/61cl   ..........A......................................................................................... 100 
JCV/CT/03cl   ....S............................................................................................... 
JCV/CT/04cl   .............LD..................................................................................... 
Consensus     MEVLNLIWLLTLCSASPVFQRCFQDGAIVKQNPSKEAVTEVCLKDDVSMIKTEAKYVKNTTGTFANNIAMRKWLVADWHDCRPQKSSGGHINVIEVGDDL 
 
JCV/CO/61cl   .................................................................................................... 200 
JCV/CT/03cl   ............................................................................................S....... 
JCV/CT/04cl   .................................................................................................... 
Consensus     SLHTESYICSADCVITVDKETAQIRLQTDNTNHFEVAGTTVKSGWFKSTTYITLDQTCEHLKVSCGPKSIQFHACFNQHMSCVRFLHRTILPGSIANSIC 
 
JCV/CO/61cl   ..................S.......V.................V....................................................... 300 
JCV/CT/03cl   .............T...................V......V........................................................... 
JCV/CT/04cl   .................................................................................................... 
Consensus     QNIEIIILVTLSLVIFIFLTIVSKTYICYLLMPIFIPIAFIYGWIYNKSCKKCKLCGLVYHPFTECGTHCVCGARYETSDRMKLHRASGLCPGYKSLRAA 
               NSM 
JCV/CO/61cl   ..................I............................N..............................I..................... 400 
JCV/CT/03cl   ...............................M..............................................V....................N 
JCV/CT/04cl   ..........V...........................I....E...........I............I.........L......R...R.......... 
Consensus     RVMCKSKGPASILSIMTAVLILTFVTPISAMVIGESSEVYTLDDLPDDMVQMAERVNIYYQIIIINYGVTWAFLLLGLXLAYFFKKYQHKFLDFYAMYCE 
                                           NSM              GC 
JCV/CO/61cl   ........S...................F...A...I.....................I..AM..I.........S...........V............ 500 
JCV/CT/03cl   ...................R...............I.........................I...................................... 
JCV/CT/04cl   ...............................I.............................V...................T.................. 
Consensus     ECDMYHEKAGLTHWGDFTNKCRQCTCGQYEDVTGLMVHKKSYNCLVKYKAKWIRDILITYLXIILVKDSLLFVGATGTDFAACIDEKTVTWNCTGPFLNL 
 
JCV/CO/61cl   .........A...G..D.................N.............S................................................... 600 
JCV/CT/03cl   ............N.....................R................................................................. 
JCV/CT/04cl   ..........N.......................K................................................................. 
Consensus     GRCDKSQKKTSYADIANQLKGLGVISVLDIPMIKXMPDEISGSLKYIDNLETYHEQLTAEYAFLTRYCDYYTQYTDNSGYSQTVWRTYLRSHDFGACVVY 
 
JCV/CO/61cl   ..................................V........................V..................I..................... 700 
JCV/CT/03cl   ..................................I................................................................. 
JCV/CT/04cl   ..................................A................................................................. 
Consensus     PNQHFCRCVKYGDKCNSAKWDFANEMKTFYTGQKXKFNKDLNLALLVLHKAFRGTGTAYIAEAMARKDNGSMAHFALEVRKKFPTNALLAALIDYIVYLQ 
 
JCV/CO/61cl   ..G..A.....................P.V....N............DT.....V..........K.................................. 800 
JCV/CT/03cl   ..........................PS......S................................................................. 
JCV/CT/04cl   ...........................I......D........A.G................................................S..... 
Consensus     SLAEISTFELDEDWEDFKYKPEPTESTXQARSHRXDQYNFKNAESNSNVKVCKNIQKVLCISPRSRAKFENIIACGEHANPSVYMMPNVSIYQSNSERSH 
 
JCV/CO/61cl   ..........K......................................I...........................V...................T.. 900 
JCV/CT/03cl   ..........D..I......S...............V...................D........................................S.. 
JCV/CT/04cl   ..........E..................V.....V...........................N.................................N.. 
Consensus     YCIADSHCLEXYEVVETELLNALKKSKCWAKEMDDIILHKQSDGLRSCRMKDTGNCNVQENDWTIVLCENGNYYYSEIHKDYDKDQDVGHFCLSPRCXTI 
 
JCV/CO/61cl   ..........K.E.........................................R....................I........................ 1000 
JCV/CT/03cl   ....N.....R.............................................................I........................... 
JCV/CT/04cl   .........RS.............A............................I.............................................. 
Consensus     RYPISKRHIKXCNWQISHSTIDKISVQELADIEQYKKAISQKLQTSLSIFKYVKTKNLPHIKPAYKYITVEGVETVEGIENAFIESEIPALAGTAIGFKI 
 
JCV/CO/61cl   ......................V...............K...........I................................................. 1100 
JCV/CT/03cl   .................................................................................................... 
JCV/CT/04cl   .................................................................................................... 
Consensus     NSREGNYLMDVIGYVKSASYSATYTKLYTTGPTIGINTRHDEKCTGPCPAVIDHKDGWLTFSKERTSTWGCEEFGCLAVSDGCVFGSCQDIIKDELAVYR 
 
JCV/CO/61cl   ....................................................I..................................S............ 1200 
JCV/CT/03cl   .......................................................................................M.K.......... 
JCV/CT/04cl   ...........................................A.....I.....................................A............ 
Consensus     KTTEELTTVELCLTFSDKTYCTNLNAITPIITDKFEVQFKTVESYTLPRVIAVKNHEIKVGQINDLGVYSKGCGNVQKVNGTNYGNGXPRFDYLCHLASR 
 
JCV/CO/61cl   .............................................................N..............D.....................T. 1300 
JCV/CT/03cl   ...................................I................................................................ 
JCV/CT/04cl   ...........................................................F.................................T...... 
Consensus     KEVILRKCFDNDYQACKFLQSPSSYRLEEHQGTVTVIDYKKILGTIKMKAILGDVKYKNYQSNIEINAEGTCAGCINCFENIHCEFTIHTTVEASCPIVT 
 
JCV/CO/61cl   E....................I..H...............V..A..................T..................................... 1400 
JCV/CT/03cl   .................................................................K.................................. 
JCV/CT/04cl   .................................................................................................... 
Consensus     DCVSFHDRILITPDEHKYALKVVCQDKPKVSLKFKICNTNIDASMTIVDSKPILELAPVDQTAYIREKDERCKTWMCRVRDEGFQVILEPFKNLFGSYIG 
 
JCV/CO/61cl   ...............V............................ 1444 
JCV/CT/03cl   ........V................................... 
JCV/CT/04cl   ............................................ 
Consensus     IFYTGILSIICLLIVIYIILPICFKLRDTLRQHEDAYKKEMKI 
Figure 2 Amino acid alignment of the predicted coding regions of the M segment. The consensus sequence consists of two or more
sequences sharing the same amino acid residue at a given position and areas of no clear consensus are indicated with an “X”.
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develop detectable viremia [23]. It is worth noting that
unlike LACV, human isolates of JCV are not available.
When such isolates are identified, it would be possible to
consider more extensive pathological studies to evaluate
the neurovirulence of JCV in non-human primates. Impor-
tantly, the three JCV strains evaluated were antigenically
similar since infection with JCV/61/CO-cl induced a
broad neutralizing antibody response against each of the
three JCV strains tested.
L segment
 
L protein 
 
JCV/CO/61cl   ......................................R............................................................. 100 
JCV/CT/03cl   ...A..........T.K......................................................E............N............... 
JCV/CT/04cl   ....................................................I............................................... 
Consensus      MDNTEYQQFLARINAARDACVAKDIDVDLLMARHDYFGKELCKSLNIEYRNDVPFVDILLDIRPDIDPLTLDIPHITPDNYLYLDNILYIIDYKVSVSNE 
 
 
JCV/CO/61cl   ...........................V........................................................................ 200 
JCV/CT/03cl   ..................I.N............................................................................... 
JCV/CT/04cl   .................................................................................................... 
Consensus      SSIITNTKYFEMTRDIASVLGLHIEIVIIRIDPISRDLYISSDRFKDLFPTLVVDINFNQFFDLKQALYEKFGDDEEFLLKVAHGDFTLTAPWCKTGCPQ 
 
JCV/CO/61cl   ...............V.................................................................................... 300 
JCV/CT/03cl   ......................................................V............D......N....................K.... 
JCV/CT/04cl   .................................................................................................... 
Consensus      VWQHPIYKEFKLSMPIPERRLFEESMKFNSYESERWNTNLIKIREYTKKEYNDFITKSAKEVFLATGNYKQPNKSEILEGWEMMVERVHQQREVSNSIHD 
 
JCV/CO/61cl   ..................................R................................................................. 400 
JCV/CT/03cl   ..........A.................................R....................................................... 
JCV/CT/04cl   .............S......................S....E.......................................................... 
Consensus      QKPSIHFIWSTHNPNNSNNATFKLILLSKSLQSIKGNSTYTDSFKSLGKMMDIGDKITDYESHCDYLKTQARLSWRQVMNKKLEPKKINDALVLWEQQFM 
 
JCV/CO/61cl   .................................................................................................... 500 
JCV/CT/03cl   .........................................................V.....T...............................I.... 
JCV/CT/04cl   .................................................................................................... 
Consensus      VNSELINKNDKLKLFRDFCGIGKHKQFKNKMLEDIELSKPKILDFNDENIYLASLTMIEQCKIMLSEQSGLKSNNFILDEFGKKIGDCNKNTLDIMTSIF 
 
JCV/CO/61cl   ..........................................I......................................................... 600 
JCV/CT/03cl   ..K.................................................................I.I............................. 
JCV/CT/04cl   .................................................................................................... 
Consensus      ETRFWQCISDFSTLMKNILSVSQYNRHNTFRIAMCANNNLFALVYPSADIKTKKATVVYSIIALHKNETDVFNPGCLHGTFKCNNGYISISRAIRLDKER  
 
JCV/CO/61cl   .................................................................................................... 700 
JCV/CT/03cl   ........................I..D.I...................................................................... 
JCV/CT/04cl   .................................................................................................... 
Consensus      CQRIVSSPGLFLTTCLLFKHENPTVRLEDVMTFSLFTSLSITKSVLSLTEPARYMIMNSLAISSNVKDYIAEKFSPYTKTLFSVYMTRLIKNACFEAYNQ 
 
JCV/CO/61cl   ..........................................................................S...S...R................. 800 
JCV/CT/03cl   ..................................C................................................................. 
JCV/CT/04cl   .................................................................................................... 
Consensus      RQKVQLRDIYLSDYDITQKGIKDNRELTSIWFPGSVTLKEYLTQIYLPFYFNAKGLHEKHHVMVDLAKTILEIENEQRNEITKIWSKDLTKQTVNLQILI  
 
JCV/CO/61cl   ......................................................I............................................. 900 
JCV/CT/03cl   .................................................H...........R.......R.............................. 
JCV/CT/04cl   ..........................................................R.R....................................... 
Consensus      HSLCKNLLADTSRHNHLRNRIENRNNFRRSITTISTFTSSKSCIKIGNFQKEKEVQYTKQKKNIEIESRKRRLANPLFVSDEEIGLEVGHCNYNMLREAM 
 
JCV/CO/61cl   .................................................................................................... 1000 
JCV/CT/03cl   .....................N...E............E............................................................. 
JCV/CT/04cl   .................................................................................................... 
Consensus      PEYRDYISTKVFDRLYEMLDTDQVSDKPTIELIMDMMADHTDFYFTFFNKGQKTSKDREIFVGEYEAKMCMYAVERIAKERCKLNPDEMISEPGDGKLKV 
 
JCV/CO/61cl   .....................G......S....................................................................... 1100 
JCV/CT/03cl   ............................A.......D............S.................................................. 
JCV/CT/04cl   ............................T....................................................................... 
Consensus      LEQKSEQEIRFLVETTRQKNREIDEAIEXLAAENFEGNISKIEKLAKGKARGLKMEINADMSKWSAQDVFFKYFWLIALDPILYPQEKERIIFFFCNYMQ 
 
JCV/CO/61cl   ...............................................................................I.................... 1200 
JCV/CT/03cl   .................................................................................................... 
JCV/CT/04cl   .................................................................................................... 
Consensus      KKLILPDDLMCNLLDQKATYRDDIISIMTNQLQTNCVEIKRNWLQGNFNYTSSYVHSCAMSVYKDVLKEAMSYLEGSIVVNSLVHSDDNQTSVTIVQDKA 
 
 
JCV/CO/61cl   .................................................................................................... 1300 
JCV/CT/03cl   .................................................................................................... 
JCV/CT/04cl   .....V....A......................................................................................... 
Consensus      PDEVLIEFSITQFQKICLAFGCQANMKKTYVTNCIKEFVSLFNLYGEPFSIYGRFLLTSVGDCAYIGPYEDLASRISSAQTAIKHGCPPSLAWVSIAISH 
 
JCV/CO/61cl   ........................N.............................................................N............. 1400 
JCV/CT/03cl   ..........................R...................................................A.......T............. 
JCV/CT/04cl   ......................................................................................S............. 
Consensus      WITGLTYNMLPGQSNDPMDYFPAETRKDIPIELNGVLDAPLSMISTVGLEAGNLWFLIKMLNKHTPIMQKRESVVNQISEIRNWDLXRMDDNEIFKLKIL 
 
JCV/CO/61cl   ..............................................................................R..................... 1500 
JCV/CT/03cl   ..........................................................D......................................... 
JCV/CT/04cl   .................................................................................................... 
Consensus      RYLVLDAEMDPSDIMGETSDMRGRSILTPRKFTTSGSLRKLYSFSKYQDRLSSPGGMNELFQYLLEKPELLVTKGEDKKDYMESVIFRYNSKRFKESLSI 
 
JCV/CO/61cl   .................V.................................................................................. 1600 
JCV/CT/03cl   ............................V....................................................................... 
JCV/CT/04cl   .................................................................................................... 
Consensus      QNPAQLFIEQILFSNKPIIDFSGIRDKYINLHDSRALEKEPDIIGKVTFREAYRILMKDLNSLPLTNDDIQVVYSYIILNDPLMITIANTQILSIYGSPQ 
 
JCV/CO/61cl   .....................................................................A.............................. 1700 
JCV/CT/03cl   ...........K........................I........................KI......L.............................. 
JCV/CT/04cl   .....................................................................M.............................. 
Consensus      KRTGMSCSTMPEFRNLKLIHHSPALVLRAYSKNTPDVQGADPTEMSRDLVHLKEFVDNTNLRTKMEKRIXENELEKGARDIVFELKEMTRFYQVCYEYIK 
 
JCV/CO/61cl   .................................................................................................... 1800 
JCV/CT/03cl   .................................................................................................... 
JCV/CT/04cl   .................................................................................................... 
Consensus      STEHKIKVFILPAKAYTTTDFCSLMQGNLIKDKEWYTVHYLKQILSGGHKAIMQHNSTSEQNIAFECFRLITHFADSFIDAGSRPAFLQLVLDSFSYKDV 
 
JCV/CO/61cl   .................................................................................................... 1900 
JCV/CT/03cl   .................................................................................................... 
JCV/CT/04cl   .................................................................................................... 
Consensus      KVNKLYEIIKNGHNRTDFIPLLFRTGDLTQYDLDKYDAMKSQERVTWNDWQTSRHLDMGAINLTISGYNRAITIIGEDNKLTYSELNITRKTPENISISG 
 
JCV/CO/61cl   .................................................................................................... 2000 
JCV/CT/03cl   ....G..................S.......................Q..................................................K. 
JCV/CT/04cl   .................................................................................................... 
Consensus      RKLLSSRHGLKFENMAKVTTYPGNYYITYRKKDRHQYIYQIHTHESILRRNEEHMAIRTRIFNEIVPVCLVNVAEIDGDQRILIRKLDYLNNDIFSLARI 
 
JCV/CO/61cl   .................................................................................................... 2100 
JCV/CT/03cl   .................................................................................................... 
JCV/CT/04cl   .................................................................................................... 
Consensus      KVGIDEYAVIKKAHFSKMVSFDGPPIKTGLLNLTELMKSQDLLNLNYDNIRNSNLISFSKIICCEGTDNIDEGLEFLSDDPMAFTEGETIHSTPIFNIYY 
 
JCV/CO/61cl   .................................................................................................... 2200 
JCV/CT/03cl   ......................N.............................K.....................................V......... 
JCV/CT/04cl   .................................................................................................... 
Consensus      SKKGERHMTYRNAIKLLIERETSNFEEAFTFYKDGFLSPENLGCLEAIISLIRVLKTNEWSTVIDKCIHICLIKNNMDYLYHKFDMPSCFIDDPISRNIN 
 
JCV/CO/61cl   ............................................................... 2263 
JCV/CT/03cl   ..............................L................................ 
JCV/CT/04cl   ............................................................... 
Consensus      WLMYRDFISTLPPTYIAPWNIMLEHFRTKCSTLIMDKMETQRNFQDFAKMMRRSEGRTNLDFS 
Figure 3 Amino acid alignment of the predicted coding regions of the L segment. The consensus sequence consists of two or more
sequences sharing the same amino acid residue at a given position and areas of no clear consensus are indicated with an “X”.
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includes JCV, are responsible for 50 to 167 reported
cases of encephalitis per year [24]. Although the major-
ity of these cases are thought to be caused by LACV
infection of children, an unknown number are likely to
be caused by JCV. However, in a prospective serological
study of patients with CNS infections in New York
State, evidence of JCV infection was demonstrated in
77% of patients, followed by LACV in 17% of patients,
snowshoe hare virus in 4% of patients, and Trivitattus
A. 
S segment 3’ non-coding region (nt 1-72): 
                 1                                                                     72              
JCV/61/CO-cl  3’ ..............................................CC..........A....C........ 5’  
JCV/03/CT-cl  3’ ............................A........................................... 5’ 
JCV/04/CT-cl  3’ ........................................................................ 5’ 
Consensus     3’ AGTAGTGTACTCCACTTGAATACTTTGAGAATATATTGAAATAAACTTCTATAGAAGGCATACTTGGTTGAT 5’                           
M segment 3’ non-coding region (nt 1-52): 
                 1                                                 52
JCV/61/CO-cl  3’ .................................................... 5’ 
JCV/03/CT-cl  3’ ....................................C.....C......... 5’ 
JCV/04/CT-cl  3’ .................................................... 5’ 
Consensus     3’ AGTAGTGTACTACCAAGTATAGAAAACGTTCAAATCTTATCTTATTCCAAAT 5’ 
 
 
L segment 3’ non-coding region (nt 1-57): 
                 1                                                      57 
JCV/61/CO-cl  3’ ..............................................C.T.....A.. 5’ 
JCV/03/CT-cl  3’ ....................................GG...C.A.C..GGA....T. 5’ 
JCV/04/CT-cl  3’ ...............................................CA........ 5’ 
Consensus     3’ AGTAGTGTACTCCTATTTACAAAACTTACAAATACAAATAATTGCTTTNATATAGCT 5’ 
B.
S segment 5’ non-coding region (nt 778-991) 
                       778                                                                                              877 
JCV/CO/61-cl 3’ .........A...C....GC....C.GTA.T...TGATATA..A...GG......TTA..T...---AA........C..........-........... 5’
JCV/CT/03-cl 3’ .G......TG.....G...........G......C------......CA.......G.......---G.........A...................... 5’
JCV/CT/04-cl 3’ ...G..CG.T..T........G...G.A......T------.G....TC.......A.......TAT..........G.....T................ 5’
Consensus    3’ TAAACAAAANCAGTAATGAAATTTTAANTAAATTTNNNNNNTAGATTNNTAAATTGNCAAATTTNNNATAATTGGTTNAAATTCAATTCTTATAATTGGC 5’
 
                878                                                                                              977 
JCV/CO/61-cl 3’ ...T................................................................................................ 5’
JCV/CT/03-cl 3’ .................................................................................................... 5’
JCV/CT/04-cl 3’ .....G.......................C..A.TA..........................T........................G............ 5’
Consensus    3’ TTCCAAAAGGTCTTATGACCATAAACATAGCAGCACAATGGGTGGGTGGTAGGGGACAGCAACTTAATAGATCTCAGGTCATTGATTTAGTTAAATGTAT 5’
 
                978            991 
JCV/CO/61-cl 3’ .................. 5’ 
JCV/CT/03-cl 3’ .................. 5’     
JCV/CT/04-cl 3’ .................. 5’ 
Consensus    3’ TCAGTGGAGCACACTACT 5’ 
 
M segment 5’ non-coding region (nt 4385-4510) 
                       4385                                                                                            4484 
JCV/CO/61-cl 3’ .G.....C..C...........G..TA....A........A...............G........................G.G................ 5’
JCV/CT/03-cl 3’ ....C........TC...T..G........A.......T..A........G................................................. 5’
JCV/CT/04-cl 3’ ...G.......GA.......A................-....A........................C.......C........................ 5’
Consensus    3’ TAATTCAGATAAGCTTGAGATATTAGTATAGGTTTAAAGTTGTTTTTGGGTTTTATAGGGGTGGGGTTAAACAAAACTGCTAAATTTATTTTAGAATCAT 5’
 
                4485                  4510 
JCV/CO/61-cl 3’ .......................... 5’  
JCV/CT/03-cl 3’ .......................... 5’ 
JCV/CT/04-cl 3’ ...G...................... 5’ 
Consensus    3’ TTAAATATACTTGGTAGCACACTACT 5’ 
 
L segment 5’ non-coding region (nt 6847-6960) 
                       6847                                                                                            6946 
JCV/CO/61-cl 3’ ...G...........T....G..AG...T....................................G.................................. 5’
JCV/CT/03-cl 3’ ..G.T.AA..............---T........G....C...T.A..........G........C........G......................... 5’
JCV/CT/04-cl 3’ ........T..............GA........T....G.A........................A.......................A.......... 5’
Consensus    3’ TAAACAGGGTGAGTACATAAAAGNNGATCTAGACATAAAATTACATAATTGGCCATATTCAAATTNAAAATATAACAGCTTATAGTATATATTTGTAAAT 5’
 
                6947      6960 
JCV/CO/61-cl 3’ .............. 5’  
JCV/CT/03-cl 3’ .............. 5’ 
JCV/CT/04-cl 3’ .............. 5’ 
Consensus    3’ AGGAGCACACTACT 5’ 
Figure 4 Alignment of 3’ (A) and 5’ (B) non-coding regions of the S, M, and L genome segments (cDNA presented). For each segment
the consensus sequence consists of two or more sequences sharing the same nucleotide at a given position and areas of no clear consensus
are indicated with an “N”, gaps in the sequences are represented by a dash (-). Underlined sequence indicates region known to be conserved
amongst all orthobunyaviruses.
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Page 7 of 11virus in 2% of patients [17]. A vaccine to protect indivi-
duals residing in areas of high transmission for LACV
or JCV could prevent this severe disease of the CNS.
At-risk groups such as constant outdoor workers includ-
ing forest rangers have a high prevalence of antibodies
to JCV [25]. Prior to the introduction of West Nile virus
(WNV) in the United States, most encephalitis cases
thought to be attributable to an arbovirus infection were
not differentiated by the specific virus species. However,
new diagnostic tools developed in response to WNV
have begun to aid in the determination of virus etiolo-
gies for many cases. However, as stated above, the speci-
fic contribution of JCV or other California encephalitis
group viruses to the overall burden of CNS disease
remains largely unknown. Surveillance of mosquito
populations for known arboviruses continues to provide
clues to the geographical distribution of the viruses and
serves to identify regions that may be at higher risk for
transmission to humans. Due to overlap in the geogra-
phical distribution of many of the California encephalitis
group viruses, an effective vaccine would need to be
multivalent or cross protective to maximize its useful-
ness. As a first step in the vaccine development process
for JCV and other members of the California encephali-
tis group of viruses, this paper provides the first full-
length genomic sequence of JCV as well as an under-
standing of the limited genetic diversity among strains
and an understanding of their replication and immuno-
genicity in mice and monkeys. These experimental ani-
mals can be used to assess level of attenuation,
immunogenicity, and efficacy of live attenuated virus
vaccine candidates.
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Figure 5 Growth kinetics of JCV isolates. Replication of JCV/61/CO-cl, JCV/03/CT-cl, and JCV/04/CT-cl in Vero (monkey kidney) or C6/36
(mosquito) cells infected at a MOI of 0.01.
Table 5 Jamestown Canyon virus strains are highly infectious for weanling Swiss Webster mice, are weakly
neuroinvasive, and differ in neurovirulence
Virus Neuroinvasiveness
a (log10 PFU) Neurovirulence
b (log10 PFU) Phenotype
e
LD50
c ID50
d LD50 ID50 Neuroinvasive Neurovirulent
JCV/61/CO 4.8 0.8 1.2 0.5 Low High
JCV/61/CO-cl > 4 0.9 0.4 0.4 Low High
JCV/03/CT > 5 < 0 3.7 0.3 Low Low
JCV/03/CT-cl > 5 < 0 > 4 -0.5 Low Low
JCV/04/CT-cl > 5 0.3 1.4 < -1 Low High
a Groups of weanling Swiss Webster mice (21-23 days old) were inoculated intraperitoneally with 100 μL of diluted virus (0 - 5 log10 PFU).
b Groups of six weanling Swiss Webster mice (21-23 days old) were inoculated intracerebrally with 10 μL of diluted virus (-1 - 4 log10 PFU).
c LD50 = Lethal dose 50%.
d ID50 = Infectious dose 50%. Infection was defined by the development of clinical disease and/or a four-fold increase in neutralizing antibody titers.
e Neuroinvasive phenotype: Low = LD50 > 3.5 log10 PFU. Neurovirulent phenotype: Low = LD50 > 3.5 log10 PFU; High = LD50 < 1.5 log10 PFU.
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Cells and viruses
C6/36 cells (Aedes albopictus) were maintained in Ear-
le’s MEM (Invitrogen, Grand Island, NY) supplemented
with 10% fetal bovine serum (HyClone, Logan, UT),
2 mM L-glutamine (Invitrogen), and 1 mM non-essential
amino acids (Invitrogen). Vero cells (African green mon-
key kidney) were maintained in OptiPRO™SFM medium
(Invitrogen) supplemented with 4 mM L-glutamine. JCV
prototype stain JCV/61/CO was obtained from Robert
Tesh at the UTMB arbovirus collection. JCV/03/CT and
JCV/04/CT were obtained from Philip Armstrong and
Theodore G. Andreadis at the Connecticut Agricultural
Experiment Station.
Isolation of biologically-cloned viruses
Biological clones were generated by terminal dilution in
Vero cell cultures for JCV/61/CO and JCV/03/CT. Virus
stocks were serially diluted in 2-fold increments and
inoculated onto 90% confluent monolayers of Vero cells
in 96-well plates using eight wells per dilution. After
five days of incubation, cell culture fluid was removed
to a holding plate, and the cell monolayers were fixed
and stained for 10 minutes with crystal violet solution
(1% crystal violet in equal volumes of ethanol and
methanol). The virus was selected as a clonal derivative
when only 1 or 2 of the 8 wells in a single dilution row
was positive for JCV CPE. Each virus was terminally
diluted three times (sequentially) and amplified in Vero
cell culture prior to further analysis.
The parental JCV/04/CT stock contained a mixture of
plaque sizes due to an unknown contaminate which pro-
duced very large plaques and a medium sized plaque that
was recognized by LACV GN monoclonal antibody
(18752, QED Bioscience, San Diego, CA). The medium-
size plaque underwent three rounds of plaque purifica-
tion and a single round of amplification in Vero cells to
obtain a homogenous stock. Plaque purification was per-
formed by infecting confluent monolayers of Vero cells
in six-well plates with serial dilutions of JCV/04/CT, and
virus was allowed to attach for one hour. Excess inocu-
lum was removed and cells were overlayed with an equal
volume mixture of 1.6% SeaPlaque agarose (Cambrex
Bioscience, Walkersville, MD) and 2X MEM (Invitrogen)
supplemented with 10% FBS and 4 mM L-glutamine. Pla-
ques were allowed to develop for 4 days and overlayed
with an additional 2 mL of 1.6% SeaPlaque agarose con-
taining 4% neutral red stock solution (3.3 g neutral red/L
PBS, Sigma-Aldrich, St. Louis, MO). After 24 hours of
additional incubation, isolated plaques were selected for
additional plaque purification and amplification and
identified as JCV. The large plaque contaminant in the
original parent stock was identified as West Nile virus.
Sequence analysis of viral genomes
Viral RNA was isolated using the MasterPure RNA Pur-
ification Kit (Epicentre Biotechnologies, Madison, WI).
Overlapping PCR fragments for the S and M segments
were generated using JCV-specific primers and Titan
one-step reverse transcription polymerase chain reaction
kit (RT-PCR) (Roche, Indianapolis, IN). For the L seg-
ment, overlapping PCR fragments were generated using
LACV and Tahyna virus-specific primers. Sequencing of
the L segment fragments was accomplished by primer
walking. Once a full-length draft sequence was
assembled, a complete set of sequencing primers was
generated and new PCR fragments were re-sequenced.
PCR fragments up to 3000 bp were purified and both
strands directly sequenced using viral specific primers in
BigDye-terminator cycle sequencing reactions analyzed
on an ABI 3730 genetic analyzer (Applied Biosystems,
Foster City, CA). Sequence data was assembled into a
consensus sequence using AutoAssembler 2.1 software
(Applied Biosystems).
Table 6 JCV/61/CO-cl infection of rhesus monkeys results in detectable viremia and a high level of neutralizing
antibody
Virus titer on indicated day (log10 PFU/mL)
a Serum neutralizing antibody titer on day 28 as assayed against indicated virus
b
Monkey # 2 4 JCV/61/CO-cl JCV/03/CT-cl JCV/04/CT-cl
A5E054 0.7 < 0.7 195 64 505
A5E060 < 0.7 < 0.7 253 72 464
A5E068 < 0.7 < 0.7 260 165 571
A5E069 2.2 < 0.7 181 97 201
A5E070 2.5 < 0.7 172 78 205
A5E073 2.5 2.0 166 73 195
A5E077 3.0 < 0.7 180 83 244
DBXG 1.9 1.9 62 18 78
GMT
c: 171 71 259
a Serum was collected on days 0, 2, 4, 5, 8, 10, and 12. Virus was only detectable on days 2 and 4 with a lower limit of detection of 0.7 log10 PFU/mL.
b Reciprocal plaque reduction neutralization titer 60% (PRNT60).
c Geometric mean titer.
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CO, viral RNA was isolated using QIAamp Viral RNA
kit (Qiagen, Valencia, CA) from virus-infected cells at
24-48 hours post infection for the 3’ untranslated region
(UTR) or from clarified cell culture fluid for the 5’ UTR.
Viral RNA was reverse transcribed using Reverse Tran-
scriptor (Roche) at 55°C with random hexamer primers
for the 5’ UTR or with genome specific primers at
60-70°C for the 3’ UTR that enhanced reverse transcrip-
tion though RNA secondary structures. cDNA was puri-
fied with High Pure PCR product purification kit
(Roche), and a poly-A tail was added to the 3’ end of
the cDNA using 5’/3’ RACE Kit, Second Generation
(Roche). Genome ends were then amplified using virus
and poly-A specific primers. Purified PCR fragments
were sequenced as described above.
Once the first and last 13 nucleotides of JCV/61/CO
were confirmed to be identical to the known consensus
sequence for all orthobunyaviruses, primers that had a
known sequence abutted to the 13 nucleotide consensus
sequence were generated: primer 1 (forward) 5’ gaccatc-
tagcgacctccacagtagtgtact 3’ and primer 2 (reverse) 5’
gaccatctagcgacctccacagtagtgtgct 3’ (underlined sequence
corresponds to virus ends). These consensus primers
were used to determine the 3’ and 5’ UTR sequence of
all remaining JCV isolates.
In vitro growth kinetics
Cloned JCV strains were used to infect 95% confluent
monolayers of C6/36 or Vero cells at a multiplicity of
infection of 0.01 and incubated for one hour to allow
v i r u st oa t t a c ht ot h ec e l l s .I n f e c t e dm o n o l a y e r sw e r e
washed twice with sterile PBS and overlaid with med-
ium. Cultures were incubated at 37°C for 7 days with
the exception of C6/36 cells which were incubated at
32°C. Tissue culture fluid (0.45 mL) was collected every
8 hours after infection for the first 2 days and once on
day 3, mixed with one-tenth volume of 10X SPG buffer
(1X concentration: 218 mM sucrose, 6 mM L-glutamic
acid, 3.8 mM dibasic potassium phosphate, pH 7.2), and
flash frozen on dry ice. Samples were titrated as
described above.
JCV inoculation of mice
The lethal dose50 (LD50) of JCV was evaluated in
outbred Swiss Webster weanling mice (Taconic Farms,
Germantown, NY). All animal experiments were carried
out in accordance with the regulations and guidelines of
the National Institutes of Health. Three week-old weanl-
ing mice (n = 6/dose) were inoculated with serial dilu-
tions of uncloned or biologically-cloned JCV in a
volume of 10 μL intracerebrally (IC) or 100 μL intraper-
itoneally (IP). The mice were anesthetized with isofluor-
ane prior to IC inoculation. All mice were carefully
observed twice daily for clinical disease including tre-
mors and limb paralysis. Because clinically moribund
mice were humanely euthanized before succumbing to
infection, moribundity served as a surrogate for the
determination of lethality. For calculations of the mouse
infectious dose50 (ID50)m i c ew e r ec o n s i d e r e dJ C V
infected if they either developed clinical disease or
demonstrated a four-fold increase in anti-JCV neutraliz-
ing antibody titers (see below for neutralization assay).
Inoculation of rhesus monkeys
Eight JCV- and LACV-seronegative rhesus macaques of
Indian origin were inoculated subcutaneously with 10
5
PFU of JCV/61/CO-cl. All monkeys were observed daily
for clinical signs of disease. Serum samples were col-
lected and frozen on days -7, 0, 2, 4, 6, 8, 10, 12, 14, 21,
28, and 42 post inoculation for determination of viremia
or neutralizing antibody titer.
Neutralization assay
Neutralizing antibody in mouse and monkey serum was
quantified by a plaque reduction neutralization assay.
Test sera were heat inactivated (56°C for 30 minutes)
and serial 2-fold dilutions beginning at 1:10 were pre-
pared in OptiMEM (Invitrogen) supplemented with 2%
FBS, 50 μg/ml gentamicin, and 0.5% human albumin
(Talecris Biotherapeutics, Inc., Research Triangle Park,
NC). JCV was diluted to a final titer of 500 PFU/mL in
the same diluent containing 10% guinea pig complement
(Cambrex Bioscience) and was added to equal volumes
of the serum dilutions and mixed well. Serum/virus mix-
ture was incubated at 37°C for 30 minutes, added to
confluent monolayers of Vero cells, and incubated for
1 hour to allow virus attachment. Cells were overlayed
with 1% methylcellulose in OptiMEM and incubated for
5 days at 37°C. After incubation, the overlay was
removed, and the monolayers were washed twice with
PBS and stained with crystal violet to allow for the enu-
meration of virus plaques. A 60% plaque-reduction neu-
tralization titer was calculated.
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